Nicotine Amphetamine Therapy for Autism Social Deficits

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current pharmaceutical drug therapies are ineffective in treating autism spectrum disorder, which leads to significant social, emotional, and cognitive challenges for individuals, along with associated conditions like anxiety, depression, and schizophrenia.

Innovation Solution

A pharmaceutical drug therapy comprising non-ionized nicotine and amphetamine, administered in specific dosages and forms to enhance compliance and efficacy, targets the nicotinic cholinergic system to improve social deficits, sensory processing, and cognitive function.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional pharmaceutical drug therapies are used for autism, then treatment is provided, but the therapies are ineffective in treating autism spectrum disorder

Engineering Contradiction:
Improvetreatment efficacyVSAvoidsocial, emotional, and cognitive challenges
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by transitioning from conventional pharmaceutical approaches to a specific combination of nicotine and amphetamine at optimized dosages. The treatment protocol specifies precise parameters including nicotine dosage (0.5-2 mg/kg body weight), amphetamine dosage (0.1-0.5 mg/kg body weight), and administration frequency (2-4 times daily), thereby transforming an ineffective general approach into a targeted effective treatment through parameter optimization

Inventive Principle:
Principle #35Parameter changes

2Reliability

If nicotine and amphetamine are administered in conventional forms, then drug delivery is provided, but compliance and efficacy are reduced

Engineering Contradiction:
Improvetreatment efficacyVSAvoidcompliance
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the physical state parameter of the drugs from conventional solid forms to liquid form. This parameter change improves compliance by enabling flexible dosing, easier administration, and better absorption, while maintaining the precise dosage parameters (nicotine 0.5-2 mg/kg, amphetamine 0.1-0.5 mg/kg) necessary for treatment efficacy

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentUS12274695B2Pharmaceutical drug therapy for autism
Publication Date: 2025.04.15 NEW PERCEPTION RES PHARM LLC
  • US12274695B2 patent drawing

AI summary

A pharmaceutical drug therapy for autism is disclosed, including a sufficient amount of nicotine and a sufficient amount of amphetamine.